BioXcel Therapeutics Beat Consensus Estimates

BioXcel Therapeutics (BTAI) reported a loss of $0.49 per share on revenue of $0.18 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.51 per share on revenue of $0.34 million. The company beat consensus estimates by 3.92% while revenue grew 51.67% on a year-over-year basis.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.